RECRUITINGOBSERVATIONAL

Clinical Characteristics of People With Long-term Type 1 Diabetes

Clinical Characteristics of People With Long-term Type 1 Diabetes: a Cohort Study

About This Trial

Type 1 diabetes (T1D) is characterized by absolute insulin deficiency. Although the discovery and application of exogenous insulin has prolonged the lifespan of T1D patients, the chronic diabetic complications caused by long-term poor glycemic control will still reduce patients' quality of life and the overall life expectancy. According to the studies focused on long-term T1D, part of the patients with long disease duration showed resistance to microvascular complications, and several protective factors have been identified. The prevalence of T1D in China is extremely low compared to that in the western world, and little is known about the characteristics of patients with long-term T1D in China. Therefore, this study is designed to collect variable clinical and laboratory features of patients with long-term T1D, explore the risk and protective factors for the development of microvascular complications, and provide reference for the prediction and prevention of these complications.

Who May Be Eligible (Plain English)

Who May Qualify: - Individuals diagnosed with type 1 diabetes(T1D) according to the 1999 World Health Organization report - Insulin dependence from disease onset - with T1D duration of ≥10 years - able to understand the procedures and methods of this study, voluntarily participate in the study, and agree to sign the willing to sign a consent form form Who Should NOT Join This Trial: - patients with type 2 diabetes, gestational diabetes, or specific types of diabetes - patients with mental disability or have any other condition or disease that may hamper compliance with the protocol Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Individuals diagnosed with type 1 diabetes(T1D) according to the 1999 World Health Organization report * Insulin dependence from disease onset * with T1D duration of ≥10 years * able to understand the procedures and methods of this study, voluntarily participate in the study, and agree to sign the informed consent form Exclusion Criteria: * patients with type 2 diabetes, gestational diabetes, or specific types of diabetes * patients with mental disability or have any other condition or disease that may hamper compliance with the protocol

Treatments Being Tested

BIOLOGICAL

Chronic hyperglycemia

For each follow-up, the glycated albumin(GA) reflecting glycemic control of the past 2-3 weeks, the glycated hemoglobin(HbA1c) reflecting glycemic control of the past 2-3 months, and the advanced glycation end products(AGEs) will be measured.

BIOLOGICAL

Residual islet function

For each follow-up, fasting and stimulated C-peptide levels will be measured.

GENETIC

Genetic variation

Genetic variations of interest will be detected with the blood sample collected at baseline.

DIETARY_SUPPLEMENT

Dietary constitutes

For each follow-up, the dietary constitutes for the past 3 days will be recorded.

GENETIC

Microbiome composition and function

For each follow-up, the fecal and oral samples will be collected for measurement.

BIOLOGICAL

Metabolome composition

For each follow-up, the serum and urine samples will be collected for measurement.

BIOLOGICAL

Composition of peripheral blood immune cells

For each follow-up, the peripheral blood mononuclear cells will be collected for measurement.

Locations (1)

Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University

Changsha, Hunan, China